Oraqix
PreclinicalSmall molecule
Oraqix is one of 48 small molecule programs targeting Drug. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
34 competitors in Drug
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Zyvox
PfizerPhase 3
Lamprene
NovartisPhase 3
Sirturo
WWim Janssens
Phase 3
Deltyba
OtsukaPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Ketalar
AAultman Health Foundation
Phase 3
T-Dxd
Daiichi SankyoPhase 3
Keytruda
Merck & Co.Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Oraqix. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details